undamentalytics Newsletter
Sign in

Cytosorbents Corp income statement

In fiscal 2025, Cytosorbents Corp reported revenue of $37.1m, up 4.1% on the year before, operating income of −$14.7m (a -39.8% margin) and net income of −$8.2m, or −$0.13 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue012451015232541433531363737
Cost of revenue—————46771111149111111
Gross profit01123610151830322122252627
Research and development33224438129161516———
Selling, general and administrative113671215212228363438343634
Operating income−4−3−5−7−9−11−10−16−19−10−23−32−32−16−15−13
Interest expense10000———————————
Income before tax−5−4−5−10−10−12−9−18−20−9−25−34−30−22−9—
Income tax—−0−0−0−0−0−1−1−1−1−1−1−1−2−0−0
Net income−5−4−5−9−9−12−8−17−19−8−25−33−29−21−8−18
Diluted EPS−$1.25−$0.75−$0.75−$1.29−$0.38−$0.46−$0.32−$0.56−$0.60−$0.20−$0.57−$0.75−$0.65−$0.38−$0.13−$0.30
Diluted shares (average)6m8m9m14m25m25m28m31m32m39m43m44m45m54m62m62m
EBITDA−4−3−5−7−9−11−10−15−18−10−22−31−30−15−14−12

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CTSO vs ECORCTSO vs UTMDCTSO vs RVP

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Cytosorbents Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytosorbents Corp.